Levrett, a Company formed to acquire a target company (or companies) with realisable or developed commercial technologies in the pharmaceutical and biotechnology sector, has told DirectorsTalk that it has appointed Whitman Howard Limited as broker to the Company with immediate effect. EGR Broking will continue to act as corporate advisor to Levrett.
Levrett is also pleased to update shareholders on the initial few months of operation following admission. After attending the premier global Biotech conference in San Francisco in January, the Company has focussed its search for an acquisition in four specific strategic sectors, being; Oncology, Diabetes, Obesity and Mental Health. The Directors have drawn on the expertise of a number of key scientific advisors in these particular sectors and have identified a number of potential acquisition targets. Levrett will continue its due diligence on these potential targets and update shareholders in due course.
Commenting, Pascal Hughes, Chief Executive Officer, said: “Following the successful Admission of Levrett to trading on the Standard List segment of the London Stock Exchange in December, I am very encouraged by the progress made to date. We are very pleased to be working with Whitman Howard, who have significant experience in this incredibly exciting sector.”
